Stockscreener 앱 받기
44.36
0.08%
-0.035
시간 외 거래:
44.50
0.14
+0.32%
전일 마감가:
$44.40
열려 있는:
$44.2
하루 거래량:
2.19M
Relative Volume:
0.82
시가총액:
$11.89B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
25.06
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
+0.43%
1개월 성능:
+9.88%
6개월 성능:
+4.70%
1년 성능:
+23.09%
1일 변동 폭
$43.85
$44.59
1주일 범위
$43.00
$44.79
52주 변동 폭
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.36 | 11.90B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-11-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 개시 | Goldman | Buy |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis shuttering Pennsylvania site, laying off 130 employees - MSN
Exelixis Inc Stock Analysis and ForecastStock Valuation Metrics & Smart Beta Strategies That Actually Work - earlytimes.in
Will Exelixis Inc. (EX9) stock outperform energy sector in 20252025 Trading Recap & Low Risk High Win Rate Picks - Newser
Will Exelixis Inc. stock attract more institutional investorsTrend Reversal & Reliable Entry Point Trade Alerts - Newser
Will Exelixis Inc. (EX9) stock beat Nasdaq index returns2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
How forex fluctuations impact Exelixis Inc. (EX9) stockRisk Management & Weekly Stock Performance Updates - Newser
Will Exelixis Inc. (EX9) stock profit from automation wave2025 Analyst Calls & Technical Confirmation Trade Alerts - Newser
Why Exelixis Inc. (EX9) stock appeals to dividend investorsTreasury Yields & AI Forecasted Stock Moves - Newser
Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report? - Yahoo Finance
Will Exelixis Inc. (EX9) stock rise with strong economyWeekly Stock Summary & Smart Money Movement Alerts - Newser
How Exelixis Inc. (EX9) stock compares with top peers2025 Market Overview & Safe Entry Momentum Stock Tips - Newser
Can Exelixis Inc. (EX9) stock beat analyst consensusWeekly Profit Analysis & Reliable Breakout Stock Forecasts - Newser
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 - Business Wire
Exelixis (NASDAQ:EXEL) shareholders have earned a 39% CAGR over the last three years - Yahoo Finance
Vascular Endothelial Growth Factor Receptor (VEGFR) - openPR.com
Is Exelixis Inc. stock a buy for dividend growthWall Street Watch & Free Community Supported Trade Ideas - Newser
How Exelixis Inc. (EX9) stock trades under stagflationQuarterly Performance Summary & Fast Entry and Exit Trade Plans - Newser
Will Exelixis Inc. (EX9) stock announce a stock split2025 Earnings Impact & Weekly Top Gainers Trade List - Newser
Can Exelixis Inc. (EX9) stock retain market dominanceRate Cut & Daily Risk Controlled Trade Plans - Newser
2 Under-the-Radar Stocks to Buy Heading Into 2026 - Finviz
2 Under-the-Radar Stocks to Buy Heading Into 2026 - The Motley Fool
EXEL (Exelixis) Earnings Yield (Joel Greenblatt) % : 7.99% (As of Sep. 2025) - GuruFocus
Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance UK
Here's Why Exelixis (EXEL) is a Strong Growth Stock - MSN
EXEL (Exelixis) Cash, Cash Equivalents, Marketable Securities : $989 Mil (As of Sep. 2025) - GuruFocus
EXEL (Exelixis) Total Assets : $2,824 Mil (As of Sep. 2025) - GuruFocus
Hedge Fund and Insider Trading News: Ray Dalio, Michael Burry, Marshall Wace, Exelixis Inc (EXEL), Monolithic Power Systems Inc (MPWR), and More - Insider Monkey
Exelixis (LTS:0IJO) FCF Yield % : 6.28 (As of Nov. 28, 2025) - GuruFocus
Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners - MSN
How (EXEL) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Aug Rallies: How Exelixis Inc. stock reacts to job market dataQuarterly Market Review & Free Weekly Chart Analysis and Trade Guides - moha.gov.vn
Exelixis (EXEL) Director Invests $1.2 Million in Company Stock - GuruFocus
Dir Johnson Buys 27,532 ($1.2M) Of Exelixis Inc [EXEL] - TradingView
Caligan-linked Exelixis director reports 27,532-share EXEL purchase - Stock Titan
Exelixis, Inc.Common Stock (NQ: EXEL - Markets Financial Content
Exelixis EVP Haley sells shares worth $3m By Investing.com - Investing.com South Africa
Exelixis Insider Sold Shares Worth $3,046,928, According to a Recent SEC Filing - marketscreener.com
EDGAR Filing Documents for 0000939767-25-000127 - SEC.gov
EXEL insider Form 4: EVP gifts 24,000 Exelixis shares - Stock Titan
Exelixis EVP Haley sells shares worth $3m - Investing.com
VP Aftab Gifts 24,000 Of Exelixis Inc [EXEL] - TradingView
Exelixis EVP Patrick J. Haley Sells Over $3 Million in Company Stock - TradingView
EXELIXIS INC (1EXEL.MI) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
Exelixis Is Focusing On Neuroendocrine Tumors — But Is a $100 Million Windfall Next? - Smartkarma
Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D - MSN
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.44%
0.91%
자본화:
|
볼륨(24시간):